Share on LinkedInShare on LinkedIn

ARTICLE · 05 JUNE 2020

Rapid Clinical Developments Increase Insider Trading Risks

Ropes & Gray LLP
Ropes & Gray LLP
Contributor
Ropes & Gray LLP

Ropes & Gray LLP

Ropes & Gray is one of the world’s most respected law firms, with offices in key business and...

View firm profile
Explore more from Ropes & Gray LLP

Across the globe, there are more than four million confirmed cases of COVID-19, while millions more are likely carrying the virus, and related deaths are over 300,000.1

United StatesCorporate/Commercial Law
Christopher P. Conniff
Christopher P. Conniff
Eve L. Shabto
Eve L. Shabto
Author LinkedIn connections

Across the globe, there are more than four million confirmed cases of COVID-19, while millions more are likely carrying the virus, and related deaths are over 300,000.1 In response, companies in the life sciences industry are not only analyzing global health data and conducting research, but also seeking to develop vaccines and treatments that target the infection caused by COVID-19.2

The urgent need for testing, vaccines and treatments is creating a surge of new research and potential breakthroughs at many pharmaceutical and life sciences companies. While this is welcome news for people around the world, it also increases the opportunities for those seeking to illegally profit from the crisis, including those wishing to trade on material, nonpublic information.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

CLIENT ALERT: 2026 Mid-Year Update On SEC And CFTC Enforcement

The SEC and CFTC have fundamentally shifted their enforcement approach in 2026, moving away from high-volume technical violations toward targeted actions addressing serious fraud and market manipulation. This mid-year update examines new leadership priorities, enhanced inter-agency coordination, revised cooperation policies, the elimination of "no-deny" settlement provisions, and a landmark Supreme Court ruling on disgorgement that collectively reshape the regulatory landscape for market participants.
United StatesCorporate/Commercial Law
Sher Tremonte
Sher Tremonte
Article

Healthcare Trends & Transactions Q2 2026

Healthcare M&A activity maintained steady momentum through Q2 2026, driven by physician practice consolidation, AI-enabled technology acquisitions, and strategic outpatient expansion. Private equity investment persisted despite intensifying regulatory scrutiny of MSO arrangements, while digital health buyers paid significant premiums for platforms demonstrating production-grade AI capabilities and proprietary data assets.
United StatesCorporate/Commercial Law
Bass, Berry & Sims PLC
Bass, Berry & Sims PLC
Article

The Big Long List Of U.S. AI Laws

State legislatures across the U.S. have enacted a complex web of AI regulations affecting private sector businesses, spanning employment decisions, healthcare applications, consumer interactions, and digital rights. These laws impose compliance obligations including bias audits, disclosure requirements, and restrictions on automated decision-making, with enforcement mechanisms ranging from regulatory oversight to private rights of action. Understanding which state laws apply to your AI systems is critical,
United StatesCorporate/Commercial Law
Taft, Stettinius & Hollister LLP
Taft, Stettinius & Hollister LLP